Zymogenetics, Inc.

Other

Osteoscreen, Inc.

Novo Nordisk A/s

Osteoscreen Ip, LLC

Virender M Labroo

Nand Baindur

Patricia A McKernan

James R Piggott

Robert R West

Theresa Martinez

Kirk G Robbins

Shirley R Gasper

Gregory R Mundy

Paul O Sheppard

Paul D Bishop

Stephen R Jaspers

Theresa A Deisher

Stephanie Beigel

Mark W Orme

Charles R Petrie

Emma E Moore

Sharon J Busby

Robert A Smith

Steven D Bain

Steven Stroop

Niels Korsgaard

Steven Bain

Tomikazu Sasaki

The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.

Methods of using motilin homologs

The topical administration of statins for the treatment of bone disorders is disclosed.

Topical administration of statins for treatment of bone disorders

Polynucleotides encoding motilin homologs

Motilin Homologs

Isoprenoid pathway inhibitors for stimulating bone growth

Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.

Calcitonin mimetics

Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C; Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optionally be fused; and R' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6 C; and the dotted lines represent optional .pi.-bonds, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. These compounds can be used in combination with other bone growth-promoting compounds and/or estrogens and/or bisphosphonates for this purpose.

Compositions and methods for stimulating bone growth

Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;

Polypeptides of from about 9-120 amino acid residues comprising a truncated segment of fibrinogen which may be flanked by elastomeric peptides, wherein the polypeptides are cross-linkable by a transglutaminase, homo- and copolymers containing such polypeptides are disclosed. The homo- and co-polymers disclosed herein are useful in tissue sealant and wound healing formulations.

Transglutaminase cross-linkable polypeptides and methods relating thereto

Predetermined combinatorial libraries of non-peptide compounds are disclosed. Compounds useful for generating such libraries are also disclosed.

Combinatorial non-peptide libraries

The present invention provides novel uses of compounds of general formula I: ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes.

Atrophy of skin/mucous membrane

Derivatized calcitonin molecules, pharmaceutical compositions comprising derivatized calcitonins, and methods of reducing serum calcium in a patient using the derivatized calcitonins are disclosed. The molecules are characterized by a derivatized amino terminus formed by combining a calcitonin with a cyclic, polycyclic or heterocyclic moiety. Multimeric forms of the molecules are also disclosed.

Derivatized calcitonins

The invention provides synthetic calcitonin mimetics. The mimetics of the present invention may include modifications that further enhance desired characteristics, such as oral bioavailability, while maintaining or enhancing inhibition of bone resorption. Related pharmaceutical compositions and methods are also disclosed.

Growing community of inventors

Mill Creek, WA, United States of America

Virender M Labroo